

Gionata Fiorino

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/298135/gionata-fiorino-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218 papers	8,979 citations	45 h-index	90 g-index
262 ext. papers	11,584 ext. citations	4.9 avg, IF	6.05 L-index

#	Paper	IF	Citations
218	JAK inhibitors in crohn's disease: ready to go?. <i>Expert Opinion on Investigational Drugs</i> , 2022 , 1-17	5.9	
217	Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study.. <i>United European Gastroenterology Journal</i> , 2022 ,	5.3	1
216	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	2
215	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	19
214	Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1432-1441	6.1	1
213	Thrombosis in IBD in the Era of JAK Inhibition. <i>Current Drug Targets</i> , 2021 , 22, 126-136	3	1
212	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2021 , 22, 370-378	3	
211	TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease. <i>Current Drug Targets</i> , 2021 , 22, 760-769	3	0
210	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
209	The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. <i>Frontiers in Immunology</i> , 2021 , 12, 611256	8.4	10
208	Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey. <i>Gastroenterology Nursing</i> , 2021 , 44, E59-E66	1	1
207	Point-of-Care Ultrasound in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 143-151.	5.5	6
206	Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. <i>United European Gastroenterology Journal</i> , 2021 , 9, 438-442	5.3	4
205	Medical therapy versus surgery in moderate-to-severe ulcerative colitis. <i>Digestive and Liver Disease</i> , 2021 , 53, 403-408	3.3	3
204	Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. <i>Digestive and Liver Disease</i> , 2021 , 53, 712-716	3.3	2
203	Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?. <i>Current Drug Targets</i> , 2021 , 22, 347-355	3	2
202	Inflammatory Bowel Disease in Migrant Populations: Should we Look Even Further Back?. <i>Current Drug Targets</i> , 2021 , 22, 1706-1715	3	0

201	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. <i>World Journal of Gastroenterology</i> , 2021 , 27, 4276-4297	5.6	2
200	Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. <i>Clinical and Translational Science</i> , 2021 ,	4.9	6
199	Adalimumab biosimilar in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 775-776	18.8	
198	Nursing-sensitive outcomes in adult inflammatory bowel disease: A systematic review. <i>Journal of Advanced Nursing</i> , 2021 , 77, 2248-2266	3.1	2
197	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211005692	4.7	1
196	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
195	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2134-2135	6.9	71
194	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , 2020 , 69, 1213-1217	19.2	208
193	The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn's disease. <i>Updates in Surgery</i> , 2020 , 72, 985-989	2.9	3
192	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 507-516	24.2	13
191	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 775-787	4.2	4
190	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 797-806	4.2	2
189	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 819-828	4.2	1
188	Proactive TDM for Crohn's Disease Patients in Clinical Remission Under Anti-TNF Treatment: Current State of Evidence. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1338-1339	1.5	
187	Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1330-1333	1.5	55
186	Impact of therapies on bowel damage in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020 , 8, 410-417	5.3	7
185	Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. <i>Pharmacological Research</i> , 2020 , 160, 105061	10.2	6
184	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 421-427	5.4	6

183	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1037-1048	1.5	30
182	Positioning Therapies in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1280-1290	6.1	30
181	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 765-773	4.2	3
180	Protecting patients with IBD during the COVID-19 pandemic. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 639	18.8	1
179	Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. <i>Digestive and Liver Disease</i> , 2020 , 52, 44-50	3.3	7
178	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 480-489	1.5	9
177	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 4-22	1.5	320
176	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 155-168	1.5	122
175	Diagnosis and Outcome of Oesophageal Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 624-629	2.5	1
174	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. <i>Digestive and Liver Disease</i> , 2020 , 52, 138-142	3.3	13
173	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e134-e136	4.5	2
172	Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners. <i>Journal of Crohns and Colitis</i> , 2020 ,	1.5	5
171	New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?. <i>Current Opinion in Pharmacology</i> , 2020 , 55, 141-150	5.1	6
170	Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy. <i>Annals of Internal Medicine</i> , 2020 , 173, 405-407	8	15
169	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1228-1235	5.3	8
168	Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 829-841	4.2	1
167	Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1719-1721	0.7	2
166	Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 1019-1028	5.1	5

165	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
164	Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1882-1883	6.9	30
163	Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2020 ,	1.5	15
162	Hyaluronan Accelerates Intestinal Mucosal Healing through Interaction with TSG-6. <i>Cells</i> , 2019 , 8,	7.9	6
161	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1399-1407	4.5	11
160	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. <i>Cells</i> , 2019 , 8,	7.9	7
159	Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819848631	4.7	33
158	Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. <i>Gastroenterology</i> , 2019 , 156, 2349-2351	13.3	1
157	Detection and management of early stage inflammatory bowel disease: an update for clinicians. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 547-555	4.2	4
156	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. <i>Digestive and Liver Disease</i> , 2019 , 51, 972-977	3.3	13
155	Psychological Functioning of Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, e112	4.5	0
154	Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. <i>Immunotherapy</i> , 2019 , 11, 565-575	3.8	2
153	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019 , 51, 632-639	3.3	22
152	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1181-1187	6.1	31
151	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 568-579	4.5	35
150	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 144-164	1.5	427
149	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 273-284	1.5	132
148	Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. <i>Cells</i> , 2019 , 8,	7.9	5

147	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX [®] (Cortiment [®]) for active, mild-to-moderate ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2019 , 7, 1171-1182	5.3	5
146	Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2397-2415	6.9	22
145	Improving the quality of surveillance colonoscopy in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 971-983	18.8	13
144	Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. <i>Current Medicinal Chemistry</i> , 2019 , 26, 280-287	4.3	5
143	Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?. <i>Current Pharmaceutical Design</i> , 2019 , 25, 47-56	3.3	2
142	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. <i>Current Pharmaceutical Design</i> , 2019 , 25, 7-12	3.3	6
141	Are Surgical Rates Decreasing in the Biological Era In IBD?. <i>Current Drug Targets</i> , 2019 , 20, 1356-1362	3	10
140	Role of Imaging in Detecting Bowel Fibrosis and Bowel Damage 2019 , 125-139		
139	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. <i>Scientific Reports</i> , 2019 , 9, 2064	4.9	32
138	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1361-1369	2.2	7
137	Biosimilars of adalimumab: the upcoming challenge in IBD. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1023-1030	5.4	13
136	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2019 , 51, 510-515	3.3	9
135	'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 127-137	1.5	23
134	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 417-423	1.5	22
133	Long-Term Safety of In Utero Exposure to Anti-TNF α Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , 2018 , 113, 396-403	0.7	92
132	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 601-606	4.5	42
131	Vedolizumab for the treatment of Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 179-189	3.9	6
130	Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 316-322	2.2	20

129	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018 , 154, 1320-1333.e10	13.3	82
128	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 76-87	13.3	29
127	Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 239-251	13.8	24
126	Can IL-23 be a good target for ulcerative colitis?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 95-102	2.5	23
125	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 1280-1287	1.5	39
124	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 623-629	5.9	3
123	Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?. <i>Current Drug Targets</i> , 2018 , 19, 748-756	3	2
122	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 1385-1391	1.5	40
121	Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 507-522	6.1	16
120	Personalizing Psychological Treatment Along the IBD Journey: From Diagnosis to Surgery. <i>Current Drug Targets</i> , 2018 , 19, 722-728	3	2
119	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 941-950	6.1	17
118	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2442-2451	14.5	42
117	JAK inhibitors: Novel developments in management of ulcerative colitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 89-93	2.5	15
116	Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 595-599	5.9	46
115	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017 , 49, 338-358	33.8	34
114	IL-23 Blockade for Crohn's disease: next generation of anti-cytokine therapy. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 457-467	5.1	12
113	Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1179-1192	6.1	54
112	The safety of biological pharmacotherapy for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 437-443	4.1	22

111	The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 233-243	4.5	96
110	Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. <i>Digestive and Liver Disease</i> , 2017 , 49, 872-877	3.3	22
109	ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 26-34	1.5	148
108	Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 256-257	1.5	2
107	Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 274-280	1.5	29
106	Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 1407-1419	1.5	51
105	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. <i>Digestion</i> , 2017 , 96, 166-172	3.6	11
104	Early intervention in Crohn's disease: towards disease modification trials. <i>Gut</i> , 2017 , 66, 2179-2187	19.2	60
103	A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort. <i>Gastroenterology</i> , 2017 , 152, S108	13.3	2
102	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. <i>Gastroenterology</i> , 2017 , 153, 1363-1377.e6	13.3	34
101	Filgotinib in Crohn's Disease: JAK Is Back. <i>Gastroenterology</i> , 2017 , 153, 603-605	13.3	12
100	Novel therapeutic targets for inflammatory bowel disease. <i>Journal of Autoimmunity</i> , 2017 , 85, 103-116	15.5	66
99	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 3-25	1.5	1087
98	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , 2017 , 49, 17-23	3.3	26
97	Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 903-905	6.1	7
96	The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. <i>Current Pharmaceutical Design</i> , 2017 , 23, 6759-6769	3.3	7
95	Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. <i>Minerva Gastroenterology</i> , 2017 , 63, 319-326	3	1
94	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1426-1432.e1	6.9	28

93	The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 503-12	4.7	15
92	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 360-70	3.3	29
91	Preventing Collateral Damage in Crohn's Disease: The Lhann Index. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 495-500	1.5	15
90	Perception of Reproductive Health in Women with Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 886-91	1.5	32
89	Emerging therapeutic targets and strategies in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 735-44	4.2	5
88	European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 802-6	2.2	5
87	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , 2016 , 65, 1447-55	19.2	102
86	Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. <i>Journal of Clinical Investigation</i> , 2016 , 126, 611-26	15.9	26
85	Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. <i>World Journal of Gastroenterology</i> , 2016 , 22, 4594-603	5.6	29
84	439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilar. <i>Gastroenterology</i> , 2016 , 150, S92	13.3	5
83	Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , 2016 , 95, e2308	1.8	51
82	Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 1362-1365	1.5	67
81	Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1385-1397.e10	6.9	219
80	Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. <i>Immunotherapy</i> , 2015 , 7, 175-90	3.8	12
79	New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 113-20	2.4	10
78	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 945-65	1.5	229
77	Adalimumab for the treatment of pediatric Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 963-72	5.1	3
76	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1324-38	0.7	1024

75	Bowel Damage as Assessed by the Lhann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 633-9	1.5	52
74	Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?. <i>Gastroenterology</i> , 2015 , 149, 1121-3	13.3	4
73	Development of the Lhann index to assess digestive tract damage in patients with Crohn's disease. <i>Gastroenterology</i> , 2015 , 148, 52-63.e3	13.3	198
72	Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1055-65	6.1	49
71	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 773-99	2.8	11
70	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 601-6	1.5	47
69	Integrins and adhesion molecules as targets to treat inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , 2015 , 25, 67-71	5.1	20
68	Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball?. <i>Gut</i> , 2015 , 64, 1347-8	19.2	2
67	The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 107-24	1.5	258
66	Golimumab: clinical update on its use for ulcerative colitis. <i>Drugs of Today</i> , 2015 , 51, 171-84	2.5	3
65	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , 2014 , 13, 751-5	13.6	59
64	Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. <i>Digestive and Liver Disease</i> , 2014 , 46, 330-4	3.3	10
63	Commentary: anaemia in inflammatory bowel disease--the most common and ignored extra intestinal manifestation. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 227-8	6.1	5
62	Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 1548-50	1.5	76
61	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014 , 46, 963-8	3.3	36
60	Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 835-46	4.2	24
59	Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2014 , 46, 135-9	3.3	29
58	Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. <i>Annals of Internal Medicine</i> , 2014 , 160, 704-11	8	158

57	Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 885-95	5.1	7
56	Commentary: Adjunct antibiotic combination therapy for ulcerative colitis--is it time to investigate <i>Fusobacterium varium</i> ?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1333	6.1	1
55	Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa. <i>Gastroenterology</i> , 2014 , 147, 1433-5	13.3	5
54	Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1368-74	4.5	45
53	The biosimilar road in inflammatory bowel disease: the right way?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 465-71	2.5	21
52	Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF- α agents. <i>Autoimmunity Reviews</i> , 2014 , 13, 15-9	13.6	113
51	Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. <i>Journal of Gastrointestinal Surgery</i> , 2014 , 18, 83-90; discussion 90-1	3.3	23
50	State of the art: psychotherapeutic interventions targeting the psychological factors involved in IBD. <i>Current Drug Targets</i> , 2014 , 15, 1020-9	3	12
49	Catching the therapeutic window of opportunity in early Crohn's disease. <i>Current Drug Targets</i> , 2014 , 15, 1056-63	3	38
48	Iron deficiency: the hidden miscreant in inflammatory bowel disease. <i>Current Drug Targets</i> , 2014 , 15, 1011-9	3	1
47	Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 3246-55	4	27
46	Mo1332 MRE and Colonoscopy Findings in Early Crohn's Disease Predict the Course of the Disease: A Prospective Observational Cohort Study. <i>Gastroenterology</i> , 2013 , 144, S-639	13.3	2
45	Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 552-5	2.4	20
44	Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis. <i>Journal of Gastrointestinal Surgery</i> , 2013 , 17, 126-32; discussion p.132	3.3	46
43	Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 277-8	6.1	1
42	First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 345-51	24.2	46
41	Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 301-6	5.1	5
40	Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 840-2	6.1	11

39	Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2013 , 173, 250-8	6.2	94
38	Commentary: antibodies reacting with the infliximab Fab portion--something new?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 552	6.1	1
37	Cross-sectional imaging modalities in Crohn's disease. <i>Digestive Diseases</i> , 2013 , 31, 199-201	3.2	9
36	Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. <i>Current Drug Targets</i> , 2013 , 14, 1444-52	3	20
35	Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1065-72	4.5	56
34	Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. <i>Current Drug Targets</i> , 2013 , 14, 1508-21	3	45
33	Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1042-7	4.5	120
32	Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?. <i>Digestive Diseases</i> , 2012 , 30, 368-75	3.2	52
31	The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. <i>Current Drug Targets</i> , 2012 , 13, 1273-9	3	3
30	Bowel damage assessment in Crohn's disease by magnetic resonance imaging. <i>Current Drug Targets</i> , 2012 , 13, 1300-7	3	6
29	Capsule endoscopy in Crohn's disease. <i>Current Drug Targets</i> , 2012 , 13, 1261-7	3	2
28	Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. <i>American Journal of Gastroenterology</i> , 2011 , 106, 762-70	0.7	43
27	A Prospective Comparison Between 1.5T Magnetic Resonance and 3T Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience. <i>Gastroenterology</i> , 2011 , 140, S-695	13.3	2
26	Mucosal healing in ulcerative colitis: where do we stand?. <i>Current Drug Targets</i> , 2011 , 12, 1417-23	3	15
25	Biological therapy for ulcerative colitis: what is after anti-TNF. <i>Current Drug Targets</i> , 2011 , 12, 1433-9	3	12
24	Familial aggregation in inflammatory bowel disease: is it genes or environment?. <i>World Journal of Gastroenterology</i> , 2011 , 17, 2715-22	5.6	34
23	The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 349-57	6.1	69
22	Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 499-500	6.1	11

21	Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF- α therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1-10	6.1	94
20	Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1073-80	4.5	165
19	Adalimumab in ulcerative colitis: hypes and hopes. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 109-16	5.4	13
18	Acute severe colitis: infliximab and/or cyclosporine?. <i>Current Drug Targets</i> , 2011 , 12, 1448-53	3	4
17	Adalimumab in Crohn's disease: tips and tricks after 5 years of clinical experience. <i>Current Medicinal Chemistry</i> , 2011 , 18, 1230-8	4.3	13
16	H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. <i>Gut</i> , 2011 , 60, 456-62	19.2	60
15	MRI in Crohn's disease--current and future clinical applications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 9, 23-31	24.2	24
14	Risk of postoperative recurrence and postoperative management of Crohn's disease. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3213-9	5.6	24
13	Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 927-928	6.1	4
12	New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. <i>Current Medicinal Chemistry</i> , 2010 , 17, 1851-7	4.3	34
11	Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2010 , 6, 567-72	5.1	31
10	M1410: Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial. <i>Gastrointestinal Endoscopy</i> , 2010 , 71, AB213-AB214	5.2	
9	The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases. <i>Digestive and Liver Disease Supplements</i> , 2010 , 4, 1-3		
8	Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report. <i>Digestive and Liver Disease Supplements</i> , 2010 , 4, 25-27		
7	Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 189-201	6.1	26
6	Anti-TNF's for postoperative recurrence in Crohn's disease: the if's and how's. <i>Current Drug Targets</i> , 2010 , 11, 219-26	3	5
5	Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner?. <i>Current Drug Targets</i> , 2010 , 11, 249-60	3	22
4	Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study. <i>World Journal of Gastroenterology</i> , 2010 , 16, 2396-400	5.6	42

- | | | | |
|---|---|-----|----|
| 3 | Anti-TNF Therapy in Inflammatory Bowel Diseases. <i>Frontiers of Gastrointestinal Research</i> , 2009 , 95-107 | | 1 |
| 2 | Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 29, 921-7 | 6.1 | 84 |
| 1 | Postoperative recurrence of Crohn's disease and videocapsule endoscopy: it is necessary to leave no stone unturned. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 1165-6 | 4.5 | 1 |